<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493738</url>
  </required_header>
  <id_info>
    <org_study_id>BR-ITR-CT-101</org_study_id>
    <nct_id>NCT02493738</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers</brief_title>
  <official_title>A Phase I Single-Center, Randomized, Open-label, Single Dose, Crossover Study in Korean Healthy Male Volunteers to Evaluate Pharmacokinetics of Lozanoc and Sporanox</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives:&#xD;
&#xD;
        -  To evaluate the pharmacokinetics (PK) of orally administered Lozanoc under fasted and&#xD;
           fed condition in healthy male subjects&#xD;
&#xD;
        -  To compare the pharmacokinetics (PK) of orally administered Lozanoc and Sporanox under&#xD;
           fed condition in healthy male subjects&#xD;
&#xD;
        -  To evaluate the safety and tolerability of single oral dose of Lozanoc and Sporanox in&#xD;
           Korean healthy male subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I Study divided into 3 parts written as bellows.&#xD;
&#xD;
      Part I. Lozanoc 50mg single dose under fed condition vs Part 2. Lozanoc 50mg single dose&#xD;
      under fasted condition vs Part 3. Sporanox 100mg single dose under fed condition&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0~120 hour after medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>0~120 hour after medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0~120 hour after medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Superficial Mycoses</condition>
  <condition>Dermatomycoses</condition>
  <condition>Candidiasis</condition>
  <condition>Histoplasmosis</condition>
  <arm_group>
    <arm_group_label>Lozanoc 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lozanoc 50mg, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sporanox 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sporanox 100mg, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lozanoc 50mg</intervention_name>
    <description>Lozanoc 50mg single dose under fed and fasted condition</description>
    <arm_group_label>Lozanoc 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sporanox 100mg</intervention_name>
    <description>Sporanox 100mg single dose under fed condition</description>
    <arm_group_label>Sporanox 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Korean male volunteers in the age between 19 and 50 years old (inclusive)&#xD;
&#xD;
          2. Subject who are able to give signed informed consent&#xD;
&#xD;
          3. Body mass index (BMI) in the range of 19 to 28 kg/m2 and weighting at least 50kg&#xD;
&#xD;
          4. Subject who are considered&#xD;
&#xD;
               -  Pre-study physical examination with no clinically significant abnormalities&#xD;
&#xD;
               -  No clinically significant medical history&#xD;
&#xD;
               -  Vital signs were to be within reference ranges, or if outside of the range, not&#xD;
                  deemed clinically significant in the opinion of the Investigator&#xD;
&#xD;
                    -  90 mmHg ≤ systolic blood pressure (sitting position) ≤ 140mmHg&#xD;
&#xD;
                    -  50 mmHg ≤ diastolic blood pressure (sitting position) ≤ 90 mmHg&#xD;
&#xD;
               -  Pre-study clinical laboratory findings were to be within reference range, or if&#xD;
                  outside of the range, not deemed clinically significant in the opinion of the&#xD;
                  Investigator&#xD;
&#xD;
               -  No clinically significant abnormalities in 12-lead ECG results&#xD;
&#xD;
          5. Agree to continue to use at least two accepted methods of birth control and not to&#xD;
             donate sperm for at least 1 days before the first dosing, during the course of the&#xD;
             study and for a period of 90days following the last dosing.&#xD;
&#xD;
               -  Acceptable methods of birth control are: female (sexual partner) hormonal&#xD;
                  contraceptives; intrauterine device; surgical sterility at least 6 months prior&#xD;
                  to screening (Ex. hysterectomy, bilateral oophorectomy, and/or tubal ligation);&#xD;
                  use diaphragm; use condom; or spermicide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded if they meet any of the following criteria:&#xD;
&#xD;
          1. History of allergy or sensitivity to any drug, including any prior serious adverse&#xD;
             reaction to antifungal agent(s)&#xD;
&#xD;
          2. History of congestive heart failure or Patients with ventricular dysfunction such as&#xD;
             congestive heart failure&#xD;
&#xD;
          3. Undergone surgery or who have a medical condition, that in the judgment of the&#xD;
             Investigator, may affect absorption, distribution, metabolism or elimination of the&#xD;
             drug product&#xD;
&#xD;
          4. Participated in a previous clinical trial within 90 days prior to screening visit&#xD;
&#xD;
          5. Donated blood or had a significant loss of blood within 60 days prior to screening&#xD;
             visit&#xD;
&#xD;
          6. Special diet or substantial changes in eating habits within 30 days prior to screening&#xD;
             visit&#xD;
&#xD;
          7. Use of any prescription medication within 14 days before screening visit&#xD;
&#xD;
          8. Use of any other OTC medication within the 7 days before screening visit&#xD;
&#xD;
          9. History of smoking within 3 months prior to screening visit&#xD;
&#xD;
         10. Have a recent history (within 2 years prior to the screening visit) of alcohol or drug&#xD;
             abuse or a positive screen for drugs of abuse at screening&#xD;
&#xD;
         11. Positive blood screen for HIV or hepatitis B or C or syphilis&#xD;
&#xD;
         12. Clinically important abnormal hepatic function test (AST, ALT greater than 2 fold of&#xD;
             reference upper limit (ULN), or total bilirubin greater than 1.5 x ULN)&#xD;
&#xD;
         13. Not suitable to participate in the study in the opinion of the Investigator including&#xD;
             an existing physical or mental condition that prevents compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics, Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Histoplasmosis</mesh_term>
    <mesh_term>Dermatomycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

